GlassScriptPhysician profile
Sean J Murphy
NPI 1104898717
$9,709.00
in general payments reported to CMS, 2019-2025
29 companies · $1,551 in 2025
The $1,551 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $434 · 2020: $274 · 2021: $1,336 · 2022: $1,728 · 2023: $1,898 · 2024: $2,487 · 2025: $1,551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,837 · Education: $99.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,837.11 |
| Education | $99.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,522.88 | 2019-2025 | |
| Genzyme Corporation | $981.22 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $851.65 | 2019-2025 | |
| Leo Pharma INC. | $797.06 | 2019-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $701.17 | 2020-2025 | Ilumya, Blu-U, Winlevi |
| Ucb, INC. | $668.16 | 2021-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $614.70 | 2021-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $610.36 | 2019-2025 | Dupixent, Libtayo |
| Pfizer INC. | $462.22 | 2021-2025 | |
| Genentech USA, INC. | $293.44 | 2019-2025 | Xolair |
| Lilly USA, LLC | $191.11 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Almirall LLC | $161.78 | 2019-2022 | |
| Amgen INC. | $148.69 | 2019-2024 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $146.58 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $68.56 | 2019-2025 | Nemluvio |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $68.52 | 2021-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Convatec INC. | $65.73 | 2024-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $64.85 | 2020-2021 | |
| Organogenesis INC. | $47.48 | 2023 | Puraply |
| Aclaris Therapeutics, INC. | $34.25 | 2019 | |
| Incyte Corporation | $33.50 | 2022 | |
| Arcutis Biotherapeutics, INC. | $27.28 | 2023 | |
| Strata Skin Sciences, INC. | $27.13 | 2021 | |
| Vyne Pharmaceuticals INC. | $26.75 | 2021 | |
| Astellas Pharma US INC | $23.86 | 2019 | |
| Organon LLC | $20.86 | 2025 | Vtama |
| Verrica Pharmaceuticals INC. | $17.23 | 2024 | Ycanth |
| Dusa Pharmaceuticals, INC. | $16.90 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $15.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.